- According to Transparency Market Research’s latest report on the global cancer diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, Increasing trend for preventive diagnosis due to escalating prevalence continues, early diagnosis enables better clinical and economical outcomes for patients are projected to drive the global cancer diagnostics market during the forecast period
- According to the report, the global cancer diagnostics market was valued at US$ 146.2 Bn in 2018 and is anticipated to expand at a CAGR of 8.8% from 2019 to 2027
Request a sample to get extensive insights into the Cancer Diagnostics Market
Increasing trend for preventive diagnosis due to escalating prevalence continues and early diagnosis enables better clinical and economical outcomes for patients: Key Drivers
- Cancer has a major impact on society across the world. It is one of the leading causes of death across the globe and is more prevalent in developed and emerging markets. According to American Cancer Society data, over 1.7 million new cancer cases are expected to be diagnosed in 2019 in the U.S. According to information published in the European Journal of Cancer, an estimated 3.9 million new cases of cancer and 1.9 million deaths due to the disease were reported in Europe in 2018.
- The alarming rate of escalating cancer prevalence compels the healthcare providers to rethink of goals of treating cancer and also focus on prevention. This would require cancer diagnostics that are not only specific and sensitive, but also capable of detecting cancer in early stages. As the prevalence of different types of cancer grows globally, it is expected to drive the global cancer diagnostics market.
- The high cost of treatment for any kind of cancer is a key driver for increasing market for diagnostic tests and procedures. Cancer is a chronic disease and usually incurs expensive treatment along with debilitating pain, disability and in some cases death. An early detection by use of most modern diagnostics enables quick medical decision making and consequent treatment. This ensures that the cancer does not prevail until it becomes very difficult to treat. Therefore, cancer diagnostics have significant role in reduction of treatment costs, lowering of hospitalization stay, and prevention of unavoidable interventions. Early diagnosis does not necessarily mean cost saving in the treatment of disease. It allows early treatment which results into improved quality of life and ‘quality adjusted life years’ (QALY) gained. The life years gained suffices the justification of even costlier cancer diagnostics and thus provides even better outlook for the Cancer Diagnostics Market
Novel Diagnostic Biomarkers Continue To Create New Revenue Stream Boost Market Growth
- The increased knowledge about specific cancer biomarkers is providing great market opportunity to treat cancer patients through improvement in the detection. The technological advancements in the field of biotechnology have enabled the identification of potential cancer biomarkers and some of these biomarkers have been commercialized.
- In February 2020, Biocare Medical launched of seven novel IVD immunohistochemistry antibody markers for clinical diagnostics and research applications.
- In May 2020, BioGenex introduced three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis. The new launch includes: CD8A, CD56, CD163
- In 2014, Guardant Health introduced GUARDANT360 blood test that sequences patient’s cancer in real-time through genetic profiling of trace fragments of tumor DNA (cell-free DNA).
Lack of Sensitivity and Specificity to Hamper Market
- The success of any test to be used for screening, diagnostics or monitoring of a cancer is dependent on the specificity and sensitivity demonstrated by the test. The cancer diagnostics have to be specific to screen patients without cancer and sensitive enough to detect presence of even smallest tumor in the body. Presently, more than 1 million prostate biopsies are carried out in the U.S. and most of them are unnecessary or repeat biopsies only to ensure that a patient with cancer is not missed. It is a result of PSA test, not so specific test, being used for screening for prostate cancer. PSA test is being recommended for annual cancer screening by the American Cancer Society and the American Urologic Association. However, on the other hand, the National Cancer Institute, the American College of Physicians, and the U.S. Preventive Services Tasks Force do not recommend PSA test due of lack of evidence about specificity and its usefulness in reducing morbidity or mortality. Similarly, there is need for specific and sensitive biomarkers for detection of each cancer types that can be used for screening on wider population.
- Therefore, the growth of cancer diagnostics market is expected to be negatively affected unless specific and highly sensitive diagnostic tests are introduced in the market.
To understand how our report can bring difference to your business strategy, Ask for a brochure
Global Cancer Diagnostics Market: Competitive Landscape
- This report profiles major players in the global cancer diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
- The global cancer diagnostics market is highly fragmented, with the presence of a number of international as well as regional players
- Leading players operating in the global cancer diagnostics market are
- Abbott
- Ambry Genetics
- AstraZeneca plc
- bioMeriux SA
- Eli Lilly and Company
- Genoptix, Inc.
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Pfizer, Inc.
- among others
Stuck in a neck-to-neck competition with other brands? Request a custom report on Cancer Diagnostics Market
Global Cancer Diagnostics Market: Key Developments
Key players in the global cancer diagnostics market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global cancer diagnostics market. A few expansion strategies adopted by players operating in the global cancer diagnostics market are:
- In July 2020, F. Hoffmann-La Roche Ltd launched its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC).
- In October 2018, NeoGenomics has entered into a definitive agreement to acquire Genoptix for $125 million in cash and 1 million shares of NeoGenomics common stock. The acquisition of Genoptix enhances NeoGenomics’ leadership in the oncology test market, significantly expanding coverage of oncology practices, increasing customer reach, and leaving a better positioned for growth.
The report on the global cancer diagnostics market discussed individual strategies, followed by company profiles of manufacturers of cancer diagnostics. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global cancer diagnostics market.
Global Cancer Diagnostics Market – Segmentation
|
Method |
|
|
Application |
|
|
Region |
|
Frequently Asked Questions
What is the total market worth of cancer diagnostics market?
The global cancer diagnostics market was worth US$ 146.2 Bn and is projected to reach a value of US$ 311.1 Bn by the end of 2027
What is the anticipated CAGR of cancer diagnostics market in forecast period?
Cancer diagnostics market is anticipated to grow at a CAGR of 8.8% during the forecast period
Which region is expected to project highest market share in cancer diagnostics market?
North America accounted for a major share of the global cancer diagnostics market
What are the key driving factors for the growth of cancer diagnostics market?
Cancer diagnostics market is driven by increasing trend for preventive diagnosis due to escalating prevalence continues, early diagnosis enables better clinical and economical outcomes for patients
Who are the key players in the global cancer diagnostics market?
Key players in the global cancer diagnostics market include Abbott, Ambry Genetics, AstraZeneca plc, bioMeriux SA, Eli Lilly and Company, Genoptix, Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer, Inc
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objective
1.4. Research Highlight
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Development
4.2. Overview
4.3. Market Dynamic
4.3.1. Driver
4.3.2. Restraint
4.3.3. Opportunitie
4.4. Global Cancer Diagnostics Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario and Reimbursement
5.2. Cancer Epidemiology
5.3. List of active market participants (suppliers/distributors/manufacturers/vendors)
6. Global Cancer Diagnostics Market Analysis and Forecast, by Method
6.1. Introduction & Definition
6.1.1. Key Findings / Development
6.2. Global Cancer Diagnostics Market Value Forecast, by Method, 2017–2027
6.2.1. Biopsy
6.2.1.1. Bone Marrow Biopsy
6.2.1.2. Needle Biopsy
6.2.1.3. Endoscopic Biopsy
6.2.2. Endoscopy
6.2.2.1. Bronchoscopy
6.2.2.2. Colonoscopy
6.2.2.3. Sigmoidoscopy
6.2.2.4. Colposcopy
6.2.2.5. Other
6.2.3. Imaging
6.2.3.1. MRI Scan
6.2.3.2. PET Scan
6.2.3.3. CT Scan
6.2.3.4. Mammography
6.2.3.5. Ultrasound
6.2.4. Tumor Biomarker Test
6.2.4.1. PSA Test
6.2.4.2. CTC Test
6.2.4.3. AFP Test
6.2.4.4. CA 19-9
6.2.4.5. CA 125
6.2.4.6. EGFR
6.2.4.7. HER2
6.2.4.8. CEA
6.2.4.9. BRCA
6.2.4.10. KRA
6.2.4.11. ALK
6.3. Global Cancer Diagnostics Market Attractiveness, by Method
7. Global Cancer Diagnostics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.1.1. Key Findings / Development
7.2. Global Cancer Diagnostics Market Value Forecast, by Application, 2017–2027
7.2.1. Blood Cancer
7.2.2. Breast Cancer
7.2.3. Colorectal Cancer
7.2.4. Kidney Cancer
7.2.5. Liver Cancer
7.2.6. Lung Cancer
7.2.7. Ovarian Cancer
7.2.8. Pancreatic Cancer
7.2.9. Prostate Cancer
7.3. Global Cancer Diagnostics Market Attractiveness, by Application
8. Global Cancer Diagnostics Market Analysis and Forecast, by Region
8.1. Key Finding
8.2. Global Cancer Diagnostics Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. North America Cancer Diagnostics Market Attractiveness, by Region
9. North America Cancer Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Finding
9.2. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027
9.2.1. Biopsy
9.2.1.1. Bone Marrow Biopsy
9.2.1.2. Needle Biopsy
9.2.1.3. Endoscopic Biopsy
9.2.2. Endoscopy
9.2.2.1. Bronchoscopy
9.2.2.2. Colonoscopy
9.2.2.3. Sigmoidoscopy
9.2.2.4. Colposcopy
9.2.2.5. Other
9.2.3. Imaging
9.2.3.1. MRI Scan
9.2.3.2. PET Scan
9.2.3.3. CT Scan
9.2.3.4. Mammography
9.2.3.5. Ultrasound
9.2.4. Tumor Biomarker Test
9.2.4.1. PSA Test
9.2.4.2. CTC Test
9.2.4.3. AFP Test
9.2.4.4. CA 19-9
9.2.4.5. CA 125
9.2.4.6. EGFR
9.2.4.7. HER2
9.2.4.8. CEA
9.2.4.9. BRCA
9.2.4.10. KRA
9.2.4.11. ALK
9.3. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027
9.3.1. Blood Cancer
9.3.2. Breast Cancer
9.3.3. Colorectal Cancer
9.3.4. Kidney Cancer
9.3.5. Liver Cancer
9.3.6. Lung Cancer
9.3.7. Ovarian Cancer
9.3.8. Pancreatic Cancer
9.3.9. Prostate Cancer
9.4. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Cancer Diagnostics Market Attractiveness Analysi
9.5.1. By Method
9.5.2. By Application
9.5.3. By Country
10. Europe Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Finding
10.2. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027
10.2.1. Biopsy
10.2.1.1. Bone Marrow Biopsy
10.2.1.2. Needle Biopsy
10.2.1.3. Endoscopic Biopsy
10.2.2. Endoscopy
10.2.2.1. Bronchoscopy
10.2.2.2. Colonoscopy
10.2.2.3. Sigmoidoscopy
10.2.2.4. Colposcopy
10.2.2.5. Other
10.2.3. Imaging
10.2.3.1. MRI Scan
10.2.3.2. PET Scan
10.2.3.3. CT Scan
10.2.3.4. Mammography
10.2.3.5. Ultrasound
10.2.4. Tumor Biomarker Test
10.2.4.1. PSA Test
10.2.4.2. CTC Test
10.2.4.3. AFP Test
10.2.4.4. CA 19-9
10.2.4.5. CA 125
10.2.4.6. EGFR
10.2.4.7. HER2
10.2.4.8. CEA
10.2.4.9. BRCA
10.2.4.10. KRA
10.2.4.11. ALK
10.3. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027
10.3.1. Blood Cancer
10.3.2. Breast Cancer
10.3.3. Colorectal Cancer
10.3.4. Kidney Cancer
10.3.5. Liver Cancer
10.3.6. Lung Cancer
10.3.7. Ovarian Cancer
10.3.8. Pancreatic Cancer
10.3.9. Prostate Cancer
10.4. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Cancer Diagnostics Market Attractiveness Analysi
10.5.1. By Method
10.5.2. By Application
10.5.3. By Country/Sub-region
11. Asia Pacific Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Finding
11.2. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027
11.2.1. Biopsy
11.2.1.1. Bone Marrow Biopsy
11.2.1.2. Needle Biopsy
11.2.1.3. Endoscopic Biopsy
11.2.2. Endoscopy
11.2.2.1. Bronchoscopy
11.2.2.2. Colonoscopy
11.2.2.3. Sigmoidoscopy
11.2.2.4. Colposcopy
11.2.2.5. Other
11.2.3. Imaging
11.2.3.1. MRI Scan
11.2.3.2. PET Scan
11.2.3.3. CT Scan
11.2.3.4. Mammography
11.2.3.5. Ultrasound
11.2.4. Tumor Biomarker Test
11.2.4.1. PSA Test
11.2.4.2. CTC Test
11.2.4.3. AFP Test
11.2.4.4. CA 19-9
11.2.4.5. CA 125
11.2.4.6. EGFR
11.2.4.7. HER2
11.2.4.8. CEA
11.2.4.9. BRCA
11.2.4.10. KRA
11.2.4.11. ALK
11.3. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027
11.3.1. Blood Cancer
11.3.2. Breast Cancer
11.3.3. Colorectal Cancer
11.3.4. Kidney Cancer
11.3.5. Liver Cancer
11.3.6. Lung Cancer
11.3.7. Ovarian Cancer
11.3.8. Pancreatic Cancer
11.3.9. Prostate Cancer
11.4. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Cancer Diagnostics Market Attractiveness Analysi
11.5.1. By Method
11.5.2. By Application
11.5.3. By Country/Sub-region
12. Latin America Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Finding
12.2. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027
12.2.1. Biopsy
12.2.1.1. Bone Marrow Biopsy
12.2.1.2. Needle Biopsy
12.2.1.3. Endoscopic Biopsy
12.2.2. Endoscopy
12.2.2.1. Bronchoscopy
12.2.2.2. Colonoscopy
12.2.2.3. Sigmoidoscopy
12.2.2.4. Colposcopy
12.2.2.5. Other
12.2.3. Imaging
12.2.3.1. MRI Scan
12.2.3.2. PET Scan
12.2.3.3. CT Scan
12.2.3.4. Mammography
12.2.3.5. Ultrasound
12.2.4. Tumor Biomarker Test
12.2.4.1. PSA Test
12.2.4.2. CTC Test
12.2.4.3. AFP Test
12.2.4.4. CA 19-9
12.2.4.5. CA 125
12.2.4.6. EGFR
12.2.4.7. HER2
12.2.4.8. CEA
12.2.4.9. BRCA
12.2.4.10. KRA
12.2.4.11. ALK
12.3. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027
12.3.1. Blood Cancer
12.3.2. Breast Cancer
12.3.3. Colorectal Cancer
12.3.4. Kidney Cancer
12.3.5. Liver Cancer
12.3.6. Lung Cancer
12.3.7. Ovarian Cancer
12.3.8. Pancreatic Cancer
12.3.9. Prostate Cancer
12.4. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America Latin America
12.5. Latin America Cancer Diagnostics Market Attractiveness Analysi
12.5.1. By Method
12.5.2. By Application
12.5.3. By Country/Sub-region
13. Middle East & Africa Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Finding
13.2. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027
13.2.1. Biopsy
13.2.1.1. Bone Marrow Biopsy
13.2.1.2. Needle Biopsy
13.2.1.3. Endoscopic Biopsy
13.2.2. Endoscopy
13.2.2.1. Bronchoscopy
13.2.2.2. Colonoscopy
13.2.2.3. Sigmoidoscopy
13.2.2.4. Colposcopy
13.2.2.5. Other
13.2.3. Imaging
13.2.3.1. MRI Scan
13.2.3.2. PET Scan
13.2.3.3. CT Scan
13.2.3.4. Mammography
13.2.3.5. Ultrasound
13.2.4. Tumor Biomarker Test
13.2.4.1. PSA Test
13.2.4.2. CTC Test
13.2.4.3. AFP Test
13.2.4.4. CA 19-9
13.2.4.5. CA 125
13.2.4.6. EGFR
13.2.4.7. HER2
13.2.4.8. CEA
13.2.4.9. BRCA
13.2.4.10. KRA
13.2.4.11. ALK
13.3. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027
13.3.1. Blood Cancer
13.3.2. Breast Cancer
13.3.3. Colorectal Cancer
13.3.4. Kidney Cancer
13.3.5. Liver Cancer
13.3.6. Lung Cancer
13.3.7. Ovarian Cancer
13.3.8. Pancreatic Cancer
13.3.9. Prostate Cancer
13.4. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC Countrie
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Cancer Diagnostics Market Attractiveness Analysi
13.5.1. By Method
13.5.2. By Application
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by Tier and Size of companies)
14.2. Market Share / Position Analysis, by Company, 2018
14.3. Competitive Business Strategie
14.4. Company Profile
14.4.1. Abbott
14.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.1.2. Growth Strategie
14.4.1.3. SWOT Analysi
14.4.2. Ambry Genetics
14.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.2.2. Growth Strategie
14.4.2.3. SWOT Analysi
14.4.3. AstraZeneca plc
14.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.3.2. Growth Strategie
14.4.3.3. SWOT Analysi
14.4.4. bioMeriux SA
14.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.4.2. Growth Strategie
14.4.4.3. SWOT Analysi
14.4.5. Eli Lilly and Company
14.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.5.2. Growth Strategie
14.4.5.3. SWOT Analysi
14.4.6. Genoptix, Inc
14.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.6.2. Growth Strategie
14.4.6.3. SWOT Analysi
14.4.7. GlaxoSmithKline plc
14.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.7.2. Growth Strategie
14.4.7.3. SWOT Analysi
14.4.8. F. Hoffmann-La Roche Ltd
14.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.8.2. Growth Strategie
14.4.8.3. SWOT Analysi
14.4.9. Pfizer, Inc
14.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.9.2. Growth Strategie
14.4.9.3. SWOT Analysis
List of Table
Table 1List of Abbreviation
Table 2Market Snapshot: Global Cancer Diagnostics Market
Table 3List of Cancer Risk Factors
Table 4Estimated Incidence, 1 year, 2 years and 5 years survival
Table 5Breast Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
Table 6Lung Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
Table 7Colorectal Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
Table 8Summary of Type of Diagnostics Test in the U.S.
Table 9Event Impact Analysis: Global Cancer Diagnostics Market, 2017-2027
Table 10Global Cancer Diagnostics Market Revenue, by Method, 2017-2027 (USD) Million
Table 11Global Cancer Diagnostics Market Revenue, by Application, 2017-2027 (USD) Million
Table 12Global Cancer Diagnostics Market Revenue, by Geography, 2017-2027 (USD) Million
List of Figure
Figure 1.Global Cancer Diagnostics Market Segmentation
Figure 2.Global Cancer Diagnostics Market, by Application, 2018 (USD Million)
Figure 3.Comparative Analysis: Global Cancer Diagnostics Market, by Geography, 2018 & 2027E (Value %)
Figure 4.Porter’s Five Forces Analysis: Global Cancer Diagnostics Market
Figure 5.Market Attractiveness Analysis: Global Cancer Diagnostics Market, By Method, 2018 & 2027 (Value %)
Figure 6.Cancer Diagnostics Market: Global Market Share by Key Players, IVDs, Molecular Diagnostics and Companion Diagnostics), 2018 (Value %)
Figure 7.Cancer Diagnostics Market: Global Market Share by Key Players, 2018 (Value %)
Figure 8.Global Prostate Specific Antigen Tests Market Revenue, 2017-2027 (USD Million)
Figure 9.Global Circulating Tumor Cells (CTC) Tests Market Revenue, 2017-2027 (USD Million)
Figure 10.Global Alpha-Fetoprotein (AFP) Tests Market Revenue, 2017-2027 (USD Million)
Figure 11.Global CA 19-9 Tests Market Revenue, 2017-2027 (USD Million)
Figure 12.Global CA-125 Tests Market Revenue, 2017-2027 (USD Million)
Figure 13.Global EGFR Mutation Tests Market Revenue, 2017-2027 (USD Million)
Figure 14.Global HER2 Tests Market Revenue, 2017-2027 (USD Million)
Figure 15.Global Carcinoembryonic Antigen (CEA) Tests Market Revenue, 2017-2027 (USD Million)
Figure 16.Global BRCA Tests Market Revenue, 2017-2027 (USD Million)
Figure 17.Global KRAS Mutation Tests Market Revenue, 2017-2027 (USD Million)
Figure 18.Global Anaplastic Lymphoma Kinase (ALK) Tests Market Revenue, 2017-2027 (USD Million)
Figure 19.MRI Scan Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)
Figure 20.PET Scan Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)
Figure 21.CT Scan Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)
Figure 22.Mammography Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)
Figure 23.Ultrasound Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)
Figure 24.Global Colonoscopy Tests Market Revenue, 2017-2027 (USD Million)
Figure 25.Global Sigmoidoscopy Tests Market Revenue, 2017-2027 (USD Million)
Figure 26.Global Bronchoscopy Tests Market Revenue, 2017-2027 (USD Million)
Figure 27.Global Colposcopy Tests Market Revenue, 2017-2027 (USD Million)
Figure 28.Global Other Endoscopy Tests Market Revenue, 2017-2027 (USD Million)
Figure 29.Global Bone Marrow Biopsy Tests Market Revenue, 2017-2027 (USD Million)
Figure 30.Global Needle Biopsy Tests Market Revenue, 2017-2027 (USD Million)
Figure 31.Global Endoscopic Biopsy Tests Market Revenue, 2017-2027 (USD Million)
Figure 32.Comparative analysis: Global Cancer Diagnostics Market, by Applications, 2018 & 2027 (Value %)
Figure 33.Blood Cancer: Estimated number of new cases, all ages, both sexes (2012, 2015 & 2027)
Figure 34.Global Blood Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)
Figure 51.Comparative Analysis: Global Cancer Diagnostics Market, By Geography, 2018 & 2027 (Value %)
Figure 52.North America Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)
Figure 53.Europe Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)
Figure 54.Asia Pacific Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)
Figure 55.Rest of the World Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)
Figure 56.Abbott Laboratories : Annual Revenue, (USD Million)
Figure 57.Astra Zeneca plc: Annual Revenue, (USD Million)
Figure 58.bioMeriux SA : Annual Revenue, (USD Million)
Figure 59.Eli Lilly and Company: Annual Revenue, (USD Million)
Figure 60.GlaxoSmithKline plc: Annual Revenue, (USD Million)
Figure 61.F. Hoffmann-La Roche Ltd: Annual Revenue, (USD Million)
Figure 62.Pfizer, Inc.: Annual Revenue, (USD Million)
